MiR-128 and its target genes in tumorigenesis and metastasis

Experimental Cell Research

Volumn 319, Issue 20, 2013, Pages 3059-3064

  Li, Molin ^a   Fu, Weiming ^b   Wo, Lulu ^a   Shu, Xiaohong ^a   Liu, Fang ^a   Li, Chuangang ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Metastasis; MicroRNA 128 (miR 128); Target genes; Tumorigenesis

Indexed keywords

AROMATASE INHIBITOR; BMI1 PROTEIN; CISPLATIN; DNA; DNA DIRECTED RNA POLYMERASE III; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EXPORTIN 5; FLUOROURACIL; HISTONE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 128; NEUROTROPHIC TYROSINE KINASE RECEPTOR TYPE 3; NEUROTROPHIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAN PROTEIN; REELIN; RETINOIC ACID; RNA POLYMERASE II; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; CANCER PATIENT; CANCER RESISTANCE; CANCER TISSUE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INVASION; CELL MOTION; CELL PROLIFERATION; CELL RENEWAL; CYTOPLASM; DNA DAMAGE; DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC VARIABILITY; GLIOBLASTOMA; HAPLOTYPE MAP; HETEROZYGOSITY LOSS; HISTONE METHYLATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NERVE CELL PLASTICITY; NONHUMAN; NORTHERN BLOTTING; POINT MUTATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROCESSING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TUMOR CELL; TUMOR XENOGRAFT;

EID: 84887139031     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.07.031     Document Type: Review

References (66)

1. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post- transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 2008, 9:102-114.
2. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75(5):843-854.
3. Reinhart B.J., Slack F.J., Basson M., et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403(6772):901-906.
4. Heimberg A.M., Sempere L.F., Moy V.N., et al. MicroRNAs and the advent of vertebrate morphological complexity. Proc. Natl. Acad. Sci. USA 2008, 105(8):2946-2950.
5. Yekta S., Shih I.H., Bartel D.P. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004, 304(5670):594-596.
6. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120(1):15-20.
7. Landgraf P., Rusu M., Sheridan R., et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129(7):1401-1414.
8. Liu C.G., Calin G.A., Meloon B., et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc. Natl. Acad. Sci. USA 2004, 101(26):9740-9744.
9. Lamy P., Andersen C.L., Dyrskjøt L., et al. Are microRNAs located in genomic regions associated with cancer?. Br. J. Cancer 2006, 95(10):1415-1418.
10. Kato M., Slack F.J. microRNAs: small molecules with big roles-C. elegans to human cancer. Biol. Cell 2008, 100(2):71-81.
11. Ji J., Shi J., Budhu A., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 2009, 361(15):1437-1447.
12. Farazi T.A., Spitzer J.I., Morozov P., et al. miRNAs in human cancer. J. Pathol. 2011, 223(2):102-115.
13. Chen C.Z. MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med. 2005, 353(17):1768-1771.
14. Wang D., Qiu C., Zhang H., et al. Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One 2010, 5(9):e13067.
15. Smirnova L., Gräfe A., Seiler A., et al. Regulation of miRNA expression during neural cell specification. Eur. J. Neurosci. 2005, 21(6):1469-1477.
16. Lukiw W.J. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007, 18(3):297-300.
17. Persengiev S.P., Kondova I.I., Bontrop R.E. The impact of microRNAs on brain aging and neurodegeneration. Curr. Gerontol. Geriatr. Res. 2012, 2012:359-369.
18. Volinia S., Calin G.A., Liu C.G., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 2006, 103(7):2257-2261.
19. Roth P., Wischhusen J., Happold C., et al. A specific miRNA signature in the peripheral blood of glioblastoma patients. J. Neurochem. 2011, 118(3):449-457.
20. Bruno I.G., Karam R., Huang L., et al. Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. Mol. Cell 2011, 42(4):500-510.
21. Baskerville S., Bartel D.P. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 2005, 11(3):241-247.
22. Lutter D., Marr C., Krumsiek J., et al. Intronic microRNAs support their host genes by mediating synergistic and antagonistic regulatory effects. BMC Genomics 2010, 11:224.
23. Corcoran D.L., Pandit K.V., Gordon B., et al. Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS One 2009, 4(4):e5279.
24. Monteys A.M., Spengler R.M., Wan J., et al. Structure and activity of putative intronic miRNA promoters. RNA 2010, 16(3):495-505.
25. Muiños-Gimeno M., Montfort M., et al. Design and evaluation of a panel of single-nucleotide polymorphisms in microRNA genomic regions for association studies in human disease. Eur. J. Hum. Genet. 2010, 18(2):218-226.
26. Zhu Y.D., Wang L., Sun C., et al. Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia. Med. Oncol. 2011, 29(4):2323-2331.
27. Fulci V., Colombo T., Chiaretti S., et al. Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes Cancer 2009, 48(12):1069-1082.
28. Garzon R., Garofalo M., Martelli M.P., et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc. Natl. Acad. Sci. USA 2008, 105(10):3945-3950.
29. Novakova J., Slaby O., Vyzula R., et al. MicroRNA involvement in glioblastoma pathogenesis. Biochem. Biophys. Res. Commun. 2009, 386:1-5.
30. Pang J.C.S., Kwok W.K., Chen Z., et al. Oncogenic role of microRNAs in braintumors. Acta Neuropathol. 2009, 117:599-611.
31. Lages E., Guttin A., El Atifi M., et al. MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS One 2011, 6(5):e20600.
32. Wuchty S., Arjona D., Li A., et al. Prediction of associations between microRNAs and gene expression in glioma biology. PLoS One 2011, 6(2):e14681.
33. Venkataraman S., Alimova I., Fan R., et al. MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One 2010, 5(6):e10748.
34. Katada T., Ishiguro H., Kuwabara Y., et al. microRNA expression profile in undifferentiated gastric cancer. Int. J. Oncol. 2009, 34(2):537-542.
35. Khan A.P., Poisson L.M., Bhat V.B., et al. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol. Cell Proteomics 2010, 9(2):298-312.
36. Woo H.H., Laszlo C.F., Greco S., et al. Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152. Mol. Cancer 2012, 11(1):58.
37. Zhu Y., Yu F., Jiao Y., et al. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin. Cancer Res. 2011, 17(22):7105-7115.
38. Davis-Dusenbery B.N., Hata A. Mechanisms of control of microRNA biogenesis. J. Biochem. 2010, 148(4):381-392.
39. Maitra A., Wistuba I.I., Washington C., et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am. J. Pathol. 2001, 159(1):119-130.
40. Qian P., Banerjee A., Wu Z.S., et al. Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells. Cancer Res. 2012, 72(22):6036-6050.
41. Wistuba I.I., Behrens C., Virmani A.K., et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000, 60(7):1949-1960.
42. Weiss G.J., Bemis L.T., Nakajima E., et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol. 2008, 19(6):1053-1059.
43. Kotani A., Ha D., Schotte D., et al. A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle 2010, 9(6):1037-1042.
44. Mi S., Lu J., Sun M., et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 2007, 104(50):19971-19976.
45. Donzelli S., Fontemaggi G., Fazi F., et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 2012, 19(6):1038-1048.
46. Karimi M., Conserva F., Mahmoudi S., et al. Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells. Carcinogenesis 2010, 31(6):1045-1053.
47. Liu P., Cheng H., Roberts T.M., et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8(8):627-644.
48. Gao N., Flynn D.C., Zhang Z., et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell Physiol. 2004, 287(2):281-291.
49. Liu J., Cao L., Chen J., et al. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 2009, 459(7245):387-392.
50. Wu Z., Min L., Chen D., et al. Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma. PLoS One 2011, 6(2):e14648.
51. Douglas D., Hsu J.H., Hung L., et al. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res. 2008, 68(16):6507-6515.
52. Zencak D., Linbeek M., Kostic M., et al. Bmi1 loss Produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. J. Neurosci. 2005, 25(24):5774-5783.
53. Fasano C.A., Dimos J.T., Ivanova N.B., et al. shRNA knockdown of Bmi-1 reveals a critical role for p21-Rb pathway in NSC self-renewal during development. Cell Stem Cell 2007, 1(1):87-99.
54. Bruggeman S.W., Hulsman D., Tanger E., et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007, 12(4):328-341.
55. Godlewski J., Nowicki M.O., Bronisz A., et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008, 68(22):9125-9130.
56. Papagiannakopoulos T., Friedmann-Morvinski D., Neveu P., et al. Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. Oncogene 2012, 31(15):1884-1895.
57. Venkataraman S., Alimova I., Fan R., et al. MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One 2010, 5(6):e10748.
58. Palumbo T., Faucz F.R., Azevedo M., et al. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene 2012, 32(13):1651-1659.
59. Shi Z.M., Wang J., Yan Z., et al. MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS One 2012, 7(3):e32709.
60. Zhang Y., Chao T., Li R., et al. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J. Mol. Med. (Berl) 2009, 87(1):43-51.
61. Masri S., Liu Z., Phung S., et al. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res. Treat. 2010, 124(1):89-99.
62. Beltaifa S., Webster M.J., Ligons D.L., et al. Discordant changes in cortical TrkC mRNA and protein during the human lifespan. Eur. J. Neurosci. 2005, 21(9):2433-2444.
63. Esteban P.F., Yoon H.Y., Becker J., et al. A kinase-deficient TrkC receptor isoform activates Arf6-Rac1 signaling through the scaffold protein tamalin. J. Cell Biol. 2006, 173(2):291-299.
64. Guidi M., Muiños-Gimeno M., Kagerbauer B., et al. Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. BMC Mol. Biol. 2010, 11:95.
65. Nicoloso M.S., Spizzo R., Shimizu M., et al. MicroRNAs-the micro steering wheel of tumour metastases. Nat. Rev. Cancer 2009, 9(4):293-302.
66. Evangelisti C., Florian M.C., Massimi I., et al. MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J. 2009, 23(12):4276-4287.